A Multicenter, Dose-escalation and Dose-expansion, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy Characteristics of SCT520FF in Patients with Neovascular Age-related Macular Degeneration (phase I Portion)
Latest Information Update: 26 Feb 2025
At a glance
- Drugs SCT 520FF (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors Sinocelltech
Most Recent Events
- 20 Feb 2025 Planned initiation date changed from 20 Nov 2024 to 14 Feb 2025.
- 08 Nov 2024 New trial record